Investors
The Malta Hip
Inspired by the ankle joint, the MaltaHip is a revolutionary total hip replacement designed to mimic natural joint motion while improving longevity and reducing wear. Its unique 4-part design allows movement in three directions, enhancing range of motion and significantly lowering dislocation risk.
Developed with proven biomaterials and tested in accredited laboratories, MaltaHip demonstrates exceptional wear resistance—offering a longer-lasting solution compared to conventional implants. This breakthrough aims to transform outcomes for patients and healthcare providers alike.
A WHOLE LIFE HIP REPLACEMENT
MaltaHip is designed to offer younger, more active patients a single, lifelong solution—eliminating the need for multiple revision surgeries as they age. This means fewer operations, faster recovery, and more time living without the limits of conventional implants.
STABILITY & WIDE RANGE OF MOVEMENT
The implant’s innovative multi-part design ensures exceptional joint stability and freedom of movement, even under active or high-demand conditions. Patients can return to everyday activities and sports with confidence, knowing the risk of dislocation is significantly reduced.
IMPROVED HOSPITAL EFFICIENCY
By reducing the number of required revision surgeries, MaltaHip can lower overall surgical volumes and free up healthcare resources. This leads to cost savings, improved patient throughput, and greater sustainability through decreased clinical waste and material use.
Market Potential
Garland Surgical is positioned within a growing global market for total hip replacement, currently valued at $7.8 billion, with over 2.6 million procedures performed annually worldwide. This demand is driven by an aging population, rising obesity rates, and the increasing prevalence of osteoarthritis.
Our initial target is the U.S. market—projected at $2.35 billion with 783,000 annual procedures by 2031.
Invest
Our current seed round is a combination of £1.5m grant funding and a £2m equity raise.
Over the last 12 months we have £2.5m of the total amount committed. Minimum ticket size is £25k and we have £2m EIS advanced assurance from HMRC available for UK Investors.
£3.5m Target
The first close of this round is 30th June 2025, and the second close is 30th September 2025 so please get in contact with us to have the opportunity to invest in this exciting venture!
The Team
Our team brings together decades of expertise in orthopedic innovation, medical device engineering, and regulatory compliance. With a shared vision of transforming hip replacement technology, our specialists in biomechanics, biomaterials, and surgical design are pioneering the next generation of implants.
Backed by a strong advisory board, including leading orthopedic surgeons and industry experts, we are dedicated to advancing patient care and improving surgical outcomes.
Validation and Recognition
The project is an industrial and academic collaboration between Garland Surgical and the University of Leeds. It contributes to a £500K research project that will enable us to reach some key product development and regulatory milestones on our MaltaHip commercialisation journey. The 15 month-long undertaking will also involve collaboration with the inventing team at the University of Malta, and the Advanced Manufacturing Research Centre at the University of Sheffield.
Our Journey
Since our founding, we have achieved key milestones in innovation, funding, and development -bringing The MaltaHip closer to transforming total hip replacement.
From securing grant funding and investment rounds to collaborating with leading research institutions and advancing regulatory approvals, each step has strengthened our mission to deliver a long-lasting, high-performance hip implant.
2015-2016: €315K funding from Malta Council for Science and Technology through the FUSION: R&I Technology Development Programme + €30K from University of Malta
Funding for:
- Initial IP searches, market and economic analysis
- Employment of PhD Research Officer, manufacture of prototypes
- Initial proof of concept at Malta University and subsequent wear and particle analysis at EndoLabs, Germany
- First cadaveric implantation at University of Malta
2022: €130K Transdisciplinary Research & Knowledge Exchange (TRAKE) University of Malta: MaltaHip II Project
- Project aiming to enhance the commercial viability of the MaltaHip by expanding the size range in which it can be offered
- Looking to reduce the acetabular cup diameter to 46 mm, the smallest size in the standard range, keeping the mechanical stresses in all components at safe levels.
2022: NLC Stepping Stone Fund €100K Pre-Seed Convertible Note
- Garland Surgical Ltd Incorporated in Worcester, UK to commercialise the MaltaHip
2023: €514K Pre-Seed Investment
- Investment by NLC Stepping Stone Fund, MUIP Ltd, Simon Mifsud and Inventing Team from Malta University
- This round funded the development of the cementless MaltaHip cup, key staff hire, cadaveric testing and set up of our Maltese Subsidiary
2023: £380K Innovate UK SMART Grant
- In conjunction with Leeds University School of Biomechanical Engineering
- Development of a range of sizes and instrumentation, manufacture of prototypes and IP registration
2024: £150K West Midlands Health Tech Innovation Accelerator Grant
- Conceptualisation of MaltaHip Revision System, Cadaveric testing, purchase of a3D printer for rapid prototyping and IP registration
2025: £3.5M Seed Round
- A combination of €1.4M Grant from Malta Enterprise, and investment from The NLC Health Impact Fund, Malta VC and Angel Investors
- Engineering and finance team expansion, completion of product development work, and regulatory file preparation
Get in touch to discuss investment opportunities
We are happy to discuss investment opportunities with potential investors.
Details about latest investment opportunities can be found by clicking the get in touch button below.